CRLCharles River Laboratories

On August 28, 2026, Victoria Creamer, our Chief People Officer, adopted a 10b5-1 trading plan. The adoption of such 10b5-1 trading plan occurred during an open trading window and complied with the Company’s policies on insider trading. The first trade will not occur until November 27, 2026, at the earliest. Ms. Creamer’s plan is for the sale of up to 12,996 shares of common stock underlying stock options, based on limit orders at a specified price in accordance with the plan and terminates on the earlier of the date all the shares under the plan are sold or August 31, 2027.

On August 27, 2026, Nancy Andrews, one of our directors, adopted a 10b5-1 trading plan. The adoption of such 10b5-1 trading plan occurred during an open trading window and complied with the Company’s policies on insider trading. The first trade will not occur until November 26, 2026, at the earliest. Dr. Andrew’s plan is for the sale of up to 2,539 shares of common stock underlying stock options, based on limit orders at a specified price in accordance with the plan and terminates on the earlier of the date all the shares under the plan are sold or November 30, 2027.

On August 18, 2026, Ms. Girshick adopted a new 10b5-1 trading plan. The adoption of such 10b5-1 trading plan occurred during an open trading window and complied with the Company’s policies on insider trading. The first trade will not occur until November 20, 2026, at the earliest. Ms. Girshick’s plan is for the sale of up to (i) 14,000 shares of our common stock and (ii) 10,814 shares of common stock underlying stock options, based on limit orders at a specified price in accordance with the plan and terminates on the earlier of the date all the shares under the plan are sold or September 1, 2027.

On May 18, 2026, Birgit Girshick, our Chief Executive Officer, adopted a 10b5-1 trading plan. The adoption of such 10b5-1 trading plan occurred during an open trading window and complied with the Company’s policies on insider trading. The first trade will not occur until September 1, 2026, at the earliest. Ms. Girshick’s plan is for the sale of up to (i) 14,000 shares of our common stock and (ii) 17,314 shares of common stock underlying stock options, based on limit orders at a specified price in accordance with the plan and terminates on the earlier of the date all the shares under the plan are sold or September 1, 2027.

On March 6, 2026, Mr. Foster entered into a Rule 10b5-1 trading arrangement for the sale of up to 193,463 shares of common stock. The arrangement’s expiration date is June 7, 2028.

On March 4, 2026, Shannon Parisotto, our Corporate Executive Vice President Global Discovery and Safety Assessment, entered into a Rule 10b5-1 trading arrangement for the sale of up to 16,131 shares of common stock. The arrangement’s expiration date is January 31, 2027.

On February 19, 2025, James Foster, our Chair, President, and Chief Executive Officer, terminated a Rule 10b5-1 trading arrangement, dated February 26, 2024, for the sale of up to 129,721 shares of common stock. Mr. Foster had sold 25,000 shares, pursuant to his Rule 10b5-1 trading arrangement, on August 1, 2024. Absent such termination, the Rule 10b5-1 trading arrangement would have expired on June 30, 2026. • On March 6, 2025, Mr. Foster entered into a Rule 10b5-1 trading arrangement for the sale of up to 168,463 shares of common stock. The arrangement’s expiration date is August 21, 2027.

On February 19, 2025, Ms. Birgit Girshick, our Corporate Executive Vice President and Chief Operating Officer, terminated a Rule 10b5-1 trading arrangement, dated November 22, 2023, for the sale of up to 22,362 shares of common stock. Ms. Girshick did not sell any shares pursuant to such plan, which, absent such termination, would have expired on February 28, 2025. • On March 3, 2025, Ms. Girshick entered into a Rule 10b5-1 trading arrangement for the sale of up to 31,314 shares of common stock. The arrangement’s expiration date is August 31, 2026.

On August 19, 2024, George Massaro, one of our directors, entered into a Rule 10b5-1 trading arrangement for the sale of up to 280 shares of common stock, in connection with the vesting of 559 RSUs in May 2025, subject to certain conditions. The arrangement’s expiration date is May 18, 2025.

On March 4, 2024, Shannon Parisotto, our Corporate Executive Vice President, Global Discovery & Safety Assessment entered into a Rule 10b5-1 trading arrangement for the sale of up to 10,170 shares of common stock, subject to certain conditions. The arrangement’s expiration date is February 28, 2025.

On February 26, 2024, James Foster, our Chair, President, and Chief Executive Officer, entered into a Rule 10b5-1 trading arrangement for the sale of up to 129,721 shares of common stock. The arrangement’s expiration date is June 30, 2026.

On November 22, 2023, Ms. Girshick entered into a Rule 10b5-1 trading arrangement for the sale of up to 22,362 shares of common stock, subject to certain conditions. The arrangement’s expiration date is February 28, 2025.

On November 15, 2023, Birgit Girshick, our Corporate Executive Vice President & Chief Operating Officer, terminated a Rule 10b5-1 trading arrangement, dated February 24, 2023 for the sale of up to 25,320 shares of common stock. Ms. Girshick did not sell any shares pursuant to such plan, which, absent such termination, would have expired on February 28, 2024.

On November 14, 2023, James Foster, our Chair, President, and Chief Executive Officer, terminated a Rule 10b5-1 trading arrangement, dated February 23, 2023 for the sale of up to 112,341 shares of common stock. Mr. Foster did not sell any shares pursuant to such plan, which, absent such termination, would have expired on March 1, 2025.

On August 16, 2023, Victoria Creamer, our Corporate Executive Vice President and Chief People Officer, adopted a Rule 10b5-1 trading agreement for the sale of up to 5,526 shares of our common stock, subject to certain conditions. The arrangement’s expiration date is February 22, 2024.

On August 11, 2023, George Massaro, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement for the sale of up to 332 shares of our common stock, subject to certain conditions. The arrangement’s expiration date is May 15, 2024.